New hope for PNH: Long-Term Add-On drug shows promise
NCT ID NCT05389449
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 32 times
Summary
This study looks at the long-term safety and effectiveness of danicopan when added to standard treatment for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. About 80 adults who have already taken danicopan in a previous study will continue treatment. Researchers will monitor side effects and blood markers to see if the drug helps control the disease over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Los Angeles, California, 90089, United States
-
Research Site
Chicago, Illinois, 60612, United States
-
Research Site
Baltimore, Maryland, 21231, United States
-
Research Site
Kansas City, Missouri, 64111, United States
-
Research Site
Long Island City, New York, 11101, United States
-
Research Site
Cleveland, Ohio, 44195, United States
-
Research Site
Dallas, Texas, 75390-9047, United States
-
Research Site
Porto Alegre, 90110-270, Brazil
-
Research Site
Rio de Janeiro, 20211-080, Brazil
-
Research Site
Toronto, Ontario, M5G 2C4, Canada
-
Research Site
Brno, 625 00, Czechia
-
Research Site
Lille, 59037, France
-
Research Site
Paris, 75010, France
-
Research Site
Pessac, 33604, France
-
Research Site
Pierre-Bénite, 69495, France
-
Research Site
Athens, 11527, Greece
-
Research Site
Thessaloniki, 57010, Greece
-
Research Site
Haifa, 31048, Israel
-
Research Site
Jerusalem, 91120, Israel
-
Research Site
Avellino, 83100, Italy
-
Research Site
Bassano del Grappa, 36061, Italy
-
Research Site
Florence, 50134, Italy
-
Research Site
Milan, 20122, Italy
-
Research Site
Reggio Calabria, 89131, Italy
-
Research Site
Roma, 161, Italy
-
Research Site
Bunkyō City, 113 8603, Japan
-
Research Site
Kyoto, 605-0981, Japan
-
Research Site
Osaka, 530-8480, Japan
-
Research Site
Shibuya-ku, 150-8935, Japan
-
Research Site
Tsukuba, 305-8576, Japan
-
Research Site
Kota Kinabalu, 88586, Malaysia
-
Research Site
Kuching, 93200, Malaysia
-
Research Site
Miri, 98000, Malaysia
-
Research Site
Gdansk, 80-952, Poland
-
Research Site
Seoul, 03722, South Korea
-
Research Site
Seoul, 06591, South Korea
-
Research Site
Suwon, 16247, South Korea
-
Research Site
Badalona, 8916, Spain
-
Research Site
Barcelona, 08036, Spain
-
Research Site
Majadahonda, 28222, Spain
-
Research Site
Seville, 41013, Spain
-
Research Site
Bangkok, 10330, Thailand
-
Research Site
Airdrie, ML6 0JS, United Kingdom
-
Research Site
Leeds, LS9 7TF, United Kingdom
-
Research Site
London, SE5 9RS, United Kingdom
Conditions
Explore the condition pages connected to this study.